Designed specific solutions to your R&D projects
Company - SMALTIS

SMALTIS is a biotechnology company, specialised in the fields of bacteriology and molecular biology. Created by two young doctors in Bacteriology: Sophie Guénard and Cédric Muller, its mission is assisting public and private research laboratories in carrying out their projects. Various individualised services in bacteriology and molecular biology are available, from producing inactivation mutants to determining the levels of resistance to all types of drugs through the construction of vectors or production of plasmids.

To ensure the highest level of quality for its customers, the laboratory has been certified ISO 9001.


Our watchwords are rigour, efficiency, responsiveness and flexibility, IN COMPLETE CONFIDENTIALITY.




 September 2015 Professor Patrick PLESIAT joined the SMALTIS company.
 July 2015 SMALTIS receives CIR agreement.
 April 2015 SMALTIS is ISO 9001 : 2008 certified.
 February 2015 SMALTIS is the winner of the "réseau entreprendre de Franche-Comté".
 January 2015 The first recruitment : Marjorie Robert-Nicoud.
 April 2014 Birth of the SMALTIS company.
 February 2014 Entry in the BIOPARC building.
 November 2013 The project "GeneHome" becomes the future SMALTIS company.
 July 2013 Winner of the 15th national competition for assistance in the creation of innovative technology companies, organised by the Ministry of Higher Education and Research in partnership with Bpifrance funding.




January 2013


 Entry in the Franche Comté innovative business incubator.


Birth of the "GeneHome" project, winner of the "Entrepreneuriales 2012" competition. 




Sophie Guénard and Cédric Muller are two young Life Sciences and Health PhD graduates of the Besançon Bacteriology Laboratory (EA 4266) directed by Professor Patrick Plésiat.




Their work has been presented at various conferences and has resulted in several publications:


Guénard, S.Muller, C., Monlezun, L., Benas, P., Broutin, I., Jeannot, K., and Plesiat, P. (2013) Multiple mutations lead to MexXY/OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother.


Buyck, J. M., Guénard, S., Plesiat, P., Tulkens, P. M., and Van Bambeke, F. (2012). Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. J Antimicrob Chemother 67, 771-5.


Muller, C., Plesiat, P., and Jeannot, K. (2011). A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 55, 1211-21.


Vettoretti, L., Plesiat, P., Muller, C., El Garch, F., Phan, G., Attree, I., Ducruix, A., and Llanes, C. (2009). Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 53, 1987-97.